Lara Kavasoğlu

Dr. Lara Kavasoğlu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Medicine
Verified
Journal Article
Open access
AGAfig Gojayev
Afig Gojayev
EKEmre Karakaya
Emre Karakaya
MEMurathan Erkent
Murathan Erkent
SYSait Can Yücebaş
Sait Can Yücebaş
HAHüseyin Onur Aydin
Hüseyin Onur Aydin
SYSedat Yildirim
Sedat Yildirim
It is difficult to differentiate between non-complicated acute cholecystitis (NCAC) and complicated acute cholecystitis (CAC) preoperatively, which are two separate pathologies with different management. The aim of this study was to create an algorithm that distinguishes between CAC and NCAC using the decision tree method, which includes simple examinations. In this retrospective study, the patients were divided into 2 groups: CAC (149 patients) and NCAC (885 patients). Parameters such as patient demographic data, American Society of Anesthesiologists (ASA) score, Tokyo grade, comorbidity findings, white blood cell (WBC) count, neutrophil/lymphocyte ratio, C-reactive protein (CRP) level, albumin level, CRP/albumin ratio (CAR), and gallbladder wall thickness (GBWT) were evaluated. In this algorithm, the CRP value became a very important parameter in the distinction between NCAC and CAC. Age was an important predictive factor in patients with CRP levels >57 mg/L, and the critical value for age was 42. After the age factor, the important parameters in the decision tree were WBC and GBWT. In patients with a CRP value of ≤57 mg/L, GBWT is decisive and the critical value is 4.85 mm. Age, neutrophil/lymphocyte ratio, and WBC count were among the other important factors after GBWT. Sex, ASA score, Tokyo grade, comorbidity, CAR, and albumin value did not have an effect on the distinction between NCAC and CAC. In statistical analysis, significant differences were found groups in terms of gender (34.8% vs 51.7% male), ASA score (P < .001), Tokyo grade (P < .001), comorbidity (P < .001), albumin (4 vs 3.4 g/dL), and CAR (2.4 vs 38.4). By means of this algorithm, which includes low-cost examinations, NCAC and CAC distinction can be made easily and quickly within limited possibilities. Preoperative prediction of pathologies that are difficult to manage, such as CAC, can minimize patient morbidity and mortality.

24 August 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
HGHikmet Erhan Güven
Hikmet Erhan Güven
LKLara Kavasoğlu
Lara Kavasoğlu
George TheodorakopoulosGeorge Theodorakopoulos
George Theodorakopoulos
Background: Necrotizing fasciitis complicating diabetic foot infection requires rapid source control and is associated with substantial morbidity. A topical desiccating agent (TDA) may assist debridement by dehydrating necrotic tissue and potentially disrupting biofilm, but comparative clinical evidence is limited. Methods: We conducted a retrospective, single-center cohort study of 87 patients who underwent emergency surgery for diabetic foot-related necrotizing fasciitis between July 2023 and February 2026. Nineteen patients received a single application of TDA at the index operation in addition to standard care, and 68 received standard care without TDA. Treatment allocation was non-random and occurred in routine clinical practice. The primary outcome was the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score at Day 7. The primary analysis used linear regression adjusted for baseline LRINEC score and baseline septic status, with heteroskedasticity-consistent type 3 (HC3) standard errors. LRINEC was treated as a laboratory-based surrogate rather than as a validated treatment-response measure. C-reactive protein (CRP), white blood cell count, and glucose at Day 0 and Day 7 were summarized descriptively. Secondary clinical outcomes were 30-day major amputation and all-cause mortality. Results: The mean LRINEC score decreased from 8.58 to 2.95 in the TDA group and from 7.51 to 5.51 in the control group. The mean change was −5.63 in the TDA group and −2.00 in the control group, an unadjusted between-group difference of −3.63 points (95% confidence interval [CI], −4.83 to −2.43; p < 0.001). Baseline sepsis was more frequent in the TDA group than in the control group (89.5% vs. 51.5%). After adjustment for baseline LRINEC score and septic status, TDA exposure was associated with a 3.01-point lower Day-7 LRINEC score (95% CI, −4.00 to −2.02; p < 0.001). At Day 7, 18 of 19 TDA-treated patients (94.7%) and 34 of 68 controls (50.0%) had an LRINEC score below 6; this threshold analysis was exploratory. CRP, white blood cell count, and glucose decreased descriptively in both groups, with numerically larger reductions in the TDA group. No major amputations or deaths occurred within 30 days in either group. No TDA-related adverse event was documented in the retrospective clinical records. Conclusions: Adjunctive TDA use was associated with a lower Day-7 LRINEC score and a greater reduction from baseline. Because treatment was not randomized, baseline severity differed between groups, LRINEC is not a validated longitudinal treatment-response measure, and assessment of clinical outcomes was limited, the findings should be interpreted as exploratory associations and confirmed in prospective multicenter studies.